Evaluation of cardiac risk in rheumatoid arthritis patients befoer and after treatment of Biologics in retrospective study

Evaluation of cardiac risk in rheumatoid arthritis patients befoer and after treatment of Biologics in retrospective study - Evaluation of cardiac risk in rheumatoid arthritis patients befoer and after treatment of Biologics in retrospective study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000013885

Enrollment

100

Registered

2014-05-05

Start date

2012-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

rheumatoid arthiritis

Interventions

RA patients were scheduled to receive TCZ once a month after 24 weeks. Serum NT-pro BNP concentrations were measured simultaneously on stored baseline and 24 week samples.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Consecutive RA patients with active disease without a clinical diagnosis of cardiovascular disease were enrolled. The RA patients each had inadequate clinical response to non-biologic DMARDs. RA patients were scheduled to receive Biologics after 24 weeks

Exclusion criteria

Exclusion criteria: Exclusion criteria were diabetes, previous cardiovascular events, cardiopathy, hypertension and renal disease.

Design outcomes

Primary

Measure	Time frame
Change of NT-pro BNP after treatment at 24 weeks of Biologics.	—

Countries

Japan

Contacts

Public ContactIsamu Yokoe

Itabashi Chuo Medical Center Rheumtology

pero1995@gmail.com03-3967-0572

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026